

The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease

Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, Volume 27, 2020 - Issue 3, Pages 174-183

Maria C. Azevedo Coutinho, Nuno Cortez-Dias, Guilhermina Cantinho, Susana Gonçalves, Miguel Nobre Menezes, Tatiana Guimarães, Gustavo Lima da Silva, Ana Rita Francisco, João Agostinho, Laura Santos, Isabel Conceição & Fausto J. Pinto

Abstract

Background:

There is a growing need for a non-invasive test to detect cardiac involvement in patients with transthyretin-related hereditary amyloidosis (ATTR) caused by V30M mutation. ^{99m}Tc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy is a promising method, but its accuracy in this particular mutation remains unknown.

Methods:

A cohort of 179 patients: 92 with early-onset disease (EoD, symptoms <50-years-old), 33 with late-onset disease (LoD) and 54 asymptomatic carriers were prospectively evaluated and underwent DPD scintigraphy, which was compared with the results of echocardiogram, ambulatory blood pressure monitoring, 24 h-Holter, myocardial ¹²³I-metaiodobenzylguanidine imaging and NT-proBNP.

Results:

Amyloid cardiomyopathy, defined as septal thickness ≥ 13 mm, was present in 32 patients (17.9%) and was more frequent in those with LoD (OR: 3.68, $p = .003$). Cardiac DPD uptake was present in 22 individuals (12.3%) and correlated with parameters indicative of cardiac amyloidosis. DPD imaging was strongly influenced by the age of disease onset: among patients with myocardial thickening, cardiac DPD retention was present in 11/15 (73.3%) with LoD, in contrast to only 4/17 (26.7%) with EoD ($p = .005$). Two patients with myocardial thickening and normal DPD scintigraphy underwent endomyocardial biopsy that confirmed ATTR amyloidosis.

Conclusion:

DPD scintigraphy presents suboptimal sensitivity to detect cardiac involvement in ATTRV30M, particularly in symptomatic patients with EoD.

Keywords: Amyloidosis, DPD scintigraphy, Scintigraphy, Transthyretin